The market had a rough day yesterday where the rally from the “lows” earlier in the week faded at the end of the day. That is never a good sign.
Despite ending the day down significantly, it actually felt like a good day. I wanted to post a real quick and short note as from now on Tuesday and Thursday.
So it is obviously getting rough and we got our first peeks of panic yesterday. Most everyone seems to think that the worst is yet to come and I would.
Not much has changed sector wide since I last wrote but we did have a trade play out, although not quite the way I expected. I want to talk about.
We had our reversal yesterday that I talked about, although I had my doubts for a little while. That is probably enough to get some buying interest barring additional negative.
Not a lot of biotech news again but macro is creeping back into the discussion with China devaluing their currency. Who knows the pin action this will have on the.
I am not able to write for a couple of days and the market goes to crap, I figured you all would be able to keep down the fort better.
It is a pretty tame start to the week. I am a little surprised given that there seemed to be some bullish late Friday price and option action with concomitant.
The sector is pretty weak, which is a continuation of the past couple of days. It is not immediately clear to me the reason for the weakness as earnings have.
The sector looked like it would be off to a good start but it faded quickly. I would still argue that any movement before the GILD earnings can be quickly.
Bio Blast Pharma Ltd. (ORPN) – Nasdaq BioBlast Pharma (ORPN) is a clinical-stage biotech company, focused on treatments for rare and ultra-rare diseases, especially genetic and metabolic diseases. The company has three.
A good start to the day with earnings almost universally beats and raises. Given the strength the sector showed yesterday, this should move the group higher and increase expectations for.
The sector was green again yesterday and this morning but it does not seem to be a broad based move. The small caps appear to be underperforming and among the.
I leave town and the sector runs to new all-time highs and I come back and there is a pullback. Perhaps the market is trying to tell me something. It.
Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium (TRIL) is developing the next-generation of cancer immunotherapies. TRIL’s lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a “do not eat”.
It is a new day and apparently a new market with everything now OK. Clearly chop is the order of the summer (as is amnesia with the market having almost.
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.